CRISPR-Cas9 in Myelodysplastic Syndromes: The Potential of Editing DNMT3A, TET2, ASXL1, TP53, and SF3B1 to Prevent Disease Progression—A Literature Review
Myelodysplastic syndromes are clonal hematopoietic stem cell neoplasms characterized by ineffective hematopoiesis and a variable risk of transformation to acute myeloid leukemia. This study examines the potential of CRISPR-Cas9 editing of DNMT3A, TET2, ASXL1, TP53, and SF3B1 to prevent disease progression. A narrative...